| Clinical data | |
|---|---|
| Other names | EBDB; 3,4-Methenedioxy-α,N-diethyl-phenethylamine; 3,4-Methylenedioxy-N-ethylbutanphenamine; MDEB |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | "Probably short"[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H19NO2 |
| Molar mass | 221.300 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 176 to 177 °C (349 to 351 °F) |
| |
| |
| (verify) | |
1,3-Benzodioxolyl-N-ethylbutanamine (ethylbenzodioxolylbutanamine,EBDB, orethyl-J) is adrug of thephenethylamine,amphetamine, andphenylisobutylamine families.[1][2][3] It is theN-ethylanalogue ofbenzodioxylbutanamine (BDB; "J"), and also theα-ethyl analogue ofmethylenedioxyethylamphetamine (MDEA; "Eve").
EBDB was first synthesized byAlexander Shulgin. In his bookPiHKAL, the minimum dose consumed was 90 mgorally, and the duration is unknown.[1] EBDB produced few to no effects at the dose range tested inPiHKAL.[1]